Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1996-10-22
1998-06-16
Saunders, David
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
435 71, 435 722, 435 792, 435 794, 435332, 435346, C07K 1628, G01N 3353
Patent
active
057672474
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to anti-annexin-V monoclonal antibodies having binding specificities to antigenic determinant sites on annexin-V, a protein present in blood, plasma and/or serum of humans and mammalian animals, and, more particularly, to such anti-annexin-V monoclonal antibodies suitable for use in the immunological determination of the concentration of human annexin-V in the blood, plasma and/or serum, being present particulary in the human cardiac muscles as a marker of myocardial infarction and angina pectoris.
The present invention further relates to hybridoma cell lines producing said anti-annexin-V monoclonal antibodies and, more particularly, to such hybridoma cell lines producing the monoclonal antibodies for use in the detection and quantitative analysis of human cardiac-muscle annexin-V as a marker of myocardial infarction and angina pectoris.
The present invention also relates to a method for the detection of annexin-V in a sample and, more particularly, to a method for the detection or quantitative analysis of human cardiac-muscle annexin-V in the blood and/or serum as a marker of myocardial infarction and angina pectoris. The present invention further relates to human cardiac muscle annexin-V in the plasma and/or serum, monoclonal antibodies for use in the detection and quantitative analysis thereof and hybridoma producing such monoclonal antibodies.
In addition, the present invention relates to the development and utilization of anti-annexin-V antibodies for the measurement of annexin-V of humans and mammals and the hybridoma cell lines producing such antibodies and, more particularly, to the development and utilization of the anti-human-annexin-V antibodies for use in quick diagnosis of diseases causing sudden cellular necrosis such as myocardial infarction and angina pectoris causing an ischemic disorder, through the concentration measurement of annexin-V, a protein in the cells or blood.
BACKGROUND ART
Annexin is a calcium-binding protein being present in tissues and cells of humans and various animals, particularly in their cytoplasmic solubles. This protein is composed of families defined by the amino acid sequences and, at present, annexin I through XII are known. The protein binds to phospholipids and actin depending upon the calcium concentration, and is known to have anti-inflammatory and anticoagulant functions.
In patients suffering from tissue or cellular necrosis, due to myocardial infarction, for example, various substances contained in the necrosed cardiac-muscle cells leak into blood. The current diagnosis of acute myocardial infarction is conducted by detecting such substances in the blood and the substances are generally called myocardial-infarction markers.
Such myocardial-infarction markers to be measured in biochemical tests for use in the diagnosis of acute myocardial infarction include LD-1, AST, creatin kinase (CK), creatin kinase MB-fraction (CK-MB), myoglobin, lactic dehydrogenase (LDH), myosin light-chain I, and troponin-T (TnT). While the results or the analytical values of these myocardial-infarction markers may be employed independently or in combination in the diagnosis of myocardial-infarction, the prevailing method is to employ them in combination.
In the case of an ischemic disease such as angina pectoris, arrhythmia is observed arrhythmia within several hours after the onset of the attack, and may lead to arrhythmia death. Quick diagnosis and treatment at the early stage are therefore needed in myocardial infarction and angina pectoris.
However, regarding the above-mentioned various types of myocardial-infarction markers (all are substances leaking from the cardiac muscles into the blood) to be examined in biochemical tests for the diagnosis of acute myocardial-infarction, it has been reported that such myocardial-infarction markers reach their respective peak concentrations in the blood 7 to 78 hours after the attack of myocardial infarction. In addition, the time in which the myocardial infarction markers reach the maximal
REFERENCES:
Takei, N. et al. "Neurotrophic effects of annexin V on cultured neurons from embryonic rat brain", Neuroscience Letters (Apr., 1994) vol. 171, Nos. 1 to 2, pp. 59-62.
Sun, J. et al. "Nucleolar and cytoplasmic localization of annexin V", FEBS Lett. (1992), vol. 314, No. 3, pp. 425-429.
Culard, J. et al. "Characterization and subcellular localization of calcium-dependent phospholipid binding proteins (annexins) in normal human skin and reconstituted epidermis", J. Invest. Dermatol. (1992) vol. 98, No. 4, pp. 436-441.
Kaneko, N. et al. "Purification of cardiac annexin V from beagle dog heart and changes in its localization in the ischemic rat heart", (May 1994) vol. 9, No. 3, pp. 148-154.
Romisch, J et al. Blood Coagulation and Fibrinolysis. 3:11-17, Mar. 1992.
Seaver, Sally S. Genetic Engineerin News. 14(14): 10,21, Aug. 1994.
Harlow, E. and Lane, DP. Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. pp. 72-77, 92-97, 128-135, 141-157, 460 and 578-581, 1988.
Romisch J and Heimburger, N. Biol. Chem. Hoppe-Seyler. 371: 383-388, May 1990.
Kajita Tadahiro
Kaneko Noboru
Matsuda Ryuko
Ohta Yohsuke
International Reagents Corporation
Kaneko Noboru
Saunders David
VanderVegt F. Pierre
LandOfFree
Anti-annexin-V monoclonal antibodies, and preparation and use th does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-annexin-V monoclonal antibodies, and preparation and use th, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-annexin-V monoclonal antibodies, and preparation and use th will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1727021